JAMA Cardiology

09/01/2026

In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone consistently lowered systolic blood pressure and reduced cardiovascular deaths and heart failure events, independent of baseline blood pressure.

This randomized clinical trial analyzes whether finerenone lowers blood pressure and whether its cardiovascular benefits in patients with mildly reduced or preserved ejection fraction heart failure depend on baseline blood pressure or blood-pressure reduction.

08/31/2026

🎙️ In this special edition of the JAMA Editor's Summary podcast, JAMA Executive Editor Greg Curfman, MD, is joined by JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editors Gregg C. Fonarow, MD, and Paz Tayal, BMBCh, PhD, to discuss:

➡️ Digital outreach to improve refills,
➡️ magnetic resonance imaging guidance for implantable defibrillator use,
➡️ Adjunctive ablation strategies for ,
➡️ tools for and aortic stenosis screening, and more.

🎧 Listen now: https://ja.ma/4h5hlV1

08/31/2026

This case report discusses a case of nonbacterial thrombotic endocarditis in an adult male with non–small cell lung cancer.

This case report discusses a case of nonbacterial thrombotic endocarditis in an adult male with non–small cell lung cancer.

08/31/2026

Presented today at :

💬 Editorial by Spencer Carter, MD, and Andrew Arai, MD: In , conventional thresholds for may underestimate risk because even modest regurgitant volumes can represent a meaningful loss of effective forward flow in a restrictive, low-stroke-volume physiology.

This editorial indicates that disease-specific thresholds may improve prognostic assessment once transthyretin amyloid cardiomyopathy has been established.

https://ja.ma/4x3DkBF

08/31/2026

Presented today at :

In a multicenter cohort of patients with newly diagnosed , increasing severity by vena contracta width, effective regurgitant or***ce area, and regurgitant volume was independently associated with mortality and first heart failure hospitalization.

These findings suggest conventional grading may underestimate risk in the restrictive low-flow physiology of transthyretin amyloid cardiomyopathy.

https://ja.ma/4qJBaWh

08/30/2026

Presented today at from JAMA:

📊 Research Summary: In persistent with significant low-voltage zones, adjunctive low-voltage zone ablation improved rhythm outcomes and health-related quality of life without increasing serious adverse events.

https://ja.ma/45XOLj3

08/30/2026

Presented today at from JAMA:

💬 Editorial by Peter Kistler, MBBS, PhD, and David Chieng, MBBS, PhD: In persistent , recent randomized trials continue to support pulmonary vein isolation as the procedural foundation, while adjunctive ablation beyond the pulmonary veins remains unsettled.

Pulsed field ablation-based posterior wall isolation did not significantly reduce the primary recurrence end point, although lower atrial arrhythmia burden suggests that the choice of end point may influence how benefit is assessed.

https://ja.ma/4qL6Xpv

08/30/2026

Presented today at from JAMA:

Meta-analysis: In patients with amyloid , transthyretin -silencing therapy reduced the composite of all-cause mortality and recurrent cardiovascular events vs placebo.

Treatment also reduced all-cause and preserved functional capacity and health status, supporting transthyretin suppression as a disease-modifying strategy.

https://ja.ma/3V26RxY

08/30/2026

📊 Research Summary: In persistent with significant low-voltage zones, adjunctive low-voltage zone ablation improved rhythm outcomes and health-related quality of life without increasing serious adverse events.

This trial evaluates whether adding low-voltage zone (LVZ) ablation to pulmonary vein isolation (PVI) improves outcomes in patients with persistent atrial fibrillation and significant left atrial LVZs.

08/30/2026

💬 Editorial by Peter Kistler, MBBS, PhD, and David Chieng, MBBS, PhD: In persistent , recent randomized trials continue to support pulmonary vein isolation as the procedural foundation, while adjunctive ablation beyond the pulmonary veins remains unsettled. Pulsed field ablation–based posterior wall isolation did not significantly reduce the primary recurrence end point, although lower atrial arrhythmia burden suggests that the choice of end point may influence how benefit is assessed.

Pulmonary vein isolation (PVI) is well established as the cornerstone for catheter ablation for atrial fibrillation, although it is less efficacious in patients with persistent atrial fibrillation compared with paroxysmal atrial fibrillation. For several decades, ablation beyond PVI has shown...